Two Sigma Securities’s Grace Therapeutics GRCE Stock Holding History

Two Sigma Securities’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,515	Closed	-$7.92K	–	3582
2023 Q2	$7.92K	Buy	+2,515	New	+$7.51K	﹤0.01%	2624
2022 Q4	–	Sell	-2,823	Closed	-$10K	–	3371
2022 Q3	$10K	Sell	2,823 -1,426	-34%	-$7.03K	﹤0.01%	2404
2022 Q2	$22K	Buy	+4,249	New	+$25.8K	﹤0.01%	1947
2022 Q1	–	Sell	-2,453	Closed	-$19K	–	2597
2021 Q4	$19K	Buy	2,453 +225	+10%	+$2.03K	﹤0.01%	1416
2021 Q3	$27K	Buy	+2,228	New	+$43.9K	﹤0.01%	1443
2021 Q2	–	Sell	-1,007	Closed	-$29K	–	1763
2021 Q1	$29K	Buy	+1,007	New	+$34.9K	﹤0.01%	761
2020 Q4	–	Sell	-326	Closed	-$3K	–	2011
2020 Q3	$3K	Buy	+326	New	+$8.46K	﹤0.01%	1266

Other funds holding GRCE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TPCW

TD Private Client Wealth New York $4.82B AUM 15.21% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

IPW

Impact Partnership Wealth Marietta, Georgia $1.03B AUM 16.45% 1-Year Est. Return

Two Sigma Securities's GRCE Position: Q3 2023 in Review

Two Sigma Securities sold out of Grace Therapeutics (GRCE) in Q3 2023, closing a stake of 2,515 shares — an estimated $7.92K sold.

Two Sigma Securities first reported a position in GRCE in Q3 2020 and held it in 7 quarters. The position peaked at $29K in Q1 2021. 12 funds tracked by Wall St. Rank hold GRCE as of Q3 2023.

Two Sigma Securities reported no remaining Grace Therapeutics position as of Q3 2023 after selling out during the quarter.
Two Sigma Securities sold 2,515 Grace Therapeutics shares in Q3 2023, an estimated $7.92K.
Two Sigma Securities first reported a position in Grace Therapeutics in Q3 2020 and held it in 7 quarters.
Two Sigma Securities's Grace Therapeutics position peaked at $29K in Q1 2021.
12 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.